SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-22-003069
Filing Date
2022-05-02
Accepted
2022-05-02 07:30:12
Documents
13
Period of Report
2022-04-27
Items
Item 5.01: Changes in Control of Registrant
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K phio_8k.htm   iXBRL 8-K 30173
2 AMENDED BYLAWS phio_ex0301.htm EX-3.1 63113
  Complete submission text file 0001683168-22-003069.txt   283919

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20220427.xsd EX-101.SCH 2965
4 XBRL LABEL FILE phio-20220427_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE phio-20220427_pre.xml EX-101.PRE 22363
7 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3715
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 22879397
SIC: 2834 Pharmaceutical Preparations